The Latest Breaking News from STAA

Staar Surgical reported better-than-expected second-quarter metrics, leading STAA stock to soar to a nine-month high Thursday.

Staar Surgical (NASDAQ:STAA) has outperformed the market over the past 20 years by 5.45% on an annualized basis producing an average annual return of 12.6%. Currently, Staar Surgical has a market capitalization of $2.88 billion.

Needham is initiating coverage on STAAR Surgical Company (NASDAQ:STAA) with a Buy rating and an $87 price target. The analysts note that FDA approval of STAA's EVO Implantable Collamer Lens (ICLs) should serve as a meaningful tailwind for revenue. The Company generates most of its revenue from outside US markets. But after the FDA approval…

The FDA approved STAAR Surgical Company's (NASDAQ:STAA) EVO/EVO+ Visian Implantable Collamer Lens to correct myopia and myopia with astigmatism. Myopia, also known as nearsightedness or the need for distance vision correction. The Company, in a statement, says that the EVO lens is additive, provides quality of vision day & night, does not cause…